Less Ads, More Data, More Tools Register for FREE

Pin to quick picksInt.biotech. Share News (IBT)

Share Price Information for Int.biotech. (IBT)

Share Price is delayed by 15 minutes
Get Live Data
990.00    0.00 (0.00%)
Bid:
972.00
Ask:
994.00
Spread: 22.00 (2.263%)
Market Cap: £315.10m
IBT Live PriceLast checked at - London Stock Exchange

Intraday Int.biotech. Share Chart

Friday tips round-up: Misys, UK Mail, Intercede

Fri, 09th Apr 2010 05:49
Misys is in good health but the Independent says it has had a very good run from these shares and anyone who got in below 129.5p could happily take profits. However, that would miss out on a banking recovery, which will happen before too long, so hold.UK Mail has a low-cost network, growing market share ? and, aside from its push into packets, other initiatives such as retail logistics and "imail" (a hybrid between e-mail and letters) through which it should be able to increase sales. It also has forecast net cash of £15 million, raising the prospect of a rise in its already-generous dividend payout ? which currently provides a 5.1 per cent yield. At 333½p, up 15p, or 14 times earnings, hold on, says the Times.Shares in Intercede fell when the company, which makes software that dovetails with identity card systems, said its pre-exceptional operating profits for the full year would miss market expectations. Time to sell, then? Maybe not. At 10.1 times FinnCap's full-year forecasts, it is not at all pricey so the Independent is happy to keep buying.Yesterday's first-half figures show IBT continues to deliver increases in net asset value (NAV) ? up 8 per cent to 164p in the six months to March 31. Helped by clarity over US healthcare reforms, and a Japanese hostile bid for OSI, one of its holdings, NAV has since risen further ? to 178p.The case from here is that half a dozen of IBT's big American stocks, such as Celgene and Vertex, will report important trial results in 2010. Meanwhile, its unquoted portfolio is now of a sufficient maturity to start providing an exit. Above all, American biotech stocks, at 14 times earnings, remain inexpensive ? even more so given that, at 139¾p, IBT sits at a 22 per cent discount to NAV, and will benefit from sterling weakness. Buy, says the Times.At 150½p, up 2p, Alternative Networks shares have outperformed the FTSE all-share index by 13 per cent over the past three months. However, at nine times FinnCap's current-year forecasts, and providing a dividend yield of 5.7 per cent, they are not stretched. Buy, says the Times.Please note: Digital Look provides a round-up of news, tips and information that is impacting share prices and the market. Digital Look cannot take any responsibility for information provided by third parties. This is for your general information only as not intended to be relied upon by users in making an investment decision or any other decision. Please obtain a copy of the relevant publication and carry out your own research before considering acting on any of this information.

Related News

TRADING UPDATES: Quantum confirms high Leadville helium concentration
2 days ago

TRADING UPDATES: Quantum confirms high Leadville helium concentration

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Monday and not separately reported...

Hargreave Hale AIM VCT posts negative interim return amid volatility
8 Jun 2026

Hargreave Hale AIM VCT posts negative interim return amid volatility

(Alliance News) - Hargreave Hale AIM VCT PLC reported a negative net asset value total return in the first half of its financial year, as geopolitical...

Int.biotech. News

EARNINGS: Griffin Mining revenue jumps; Andrews Sykes holds payout
12 May 2026

EARNINGS: Griffin Mining revenue jumps; Andrews Sykes holds payout

(Alliance News) - The following is a round-up of earnings for London-listed companies, issued on Tuesday and not separately reported by Alliance News:

International Biotechnology Trust expects more M&A after Soleno deal
7 Apr 2026

International Biotechnology Trust expects more M&A after Soleno deal

(Alliance News) - International Biotechnology Trust PLC on Tuesday said another portfolio company has agreed to be taken over, the fourth such deal in...

Int'l Biotechnology Trust bullish on future biotech M&A after Soleno acquisition
7 Apr 2026

Int'l Biotechnology Trust bullish on future biotech M&A after Soleno acquisition

(Sharecast News) - Biotech investor International Biotechnology Trust has said that it expects the current wave of "frenetic" biotech M&A activity to ...

Apellis investors respond to USD5.60 billion Biogen acquisition
1 Apr 2026

Apellis investors respond to USD5.60 billion Biogen acquisition

(Alliance News) - Biotech Growth Trust PLC, International Biotechnology Trust PLC, ad RTW Biotech Opportunities Ltd have all noted the agreement annou...

Servier acquires International Biotech's Day One for USD2.5 billion
9 Mar 2026

Servier acquires International Biotech's Day One for USD2.5 billion

(Alliance News) - International Biotechnology Trust PLC on Monday said its portfolio company Day One Biopharmaceuticals Inc has agreed to be acquired ...

International Biotechnology beats benchmark with 0.7% NAV gain
6 Nov 2025

International Biotechnology beats benchmark with 0.7% NAV gain

(Alliance News) - International Biotechnology Trust PLC on Thursday said its portfolio continued to outperform the sector benchmark as the company rep...